Insulin Lispro

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus.

Lyumjev (insulin lispro injection) is indicated for treatment of adult patients with diabetes mellitus who require insulin for the control of glucose homeostasis (see 15 CLINICAL TRIALS). Lyumjev should generally be used in a regimen with intermediate- or long-acting insulin to maintain adequate glucose control (see 8 WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).

Lyumjev vials may also be used for continuous subcutaneous insulin infusion (CSII) in pump systems that are licensed in Canada for insulin infusion. Refer to the insulin infusion pump manufacturer’s user manual to see if Lyumjev can be used.

1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics (≥65 years of age): Evidence from clinical studies and experience with insulin lispro suggests that use in the geriatric population is not associated with differences in safety or effectiveness (see 8 WARNINGS AND PRECAUTIONS, Special Population).

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for the initial stabilisation of diabetes mellitus.

1 INDICATIONS AND USAGE ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

( 1 )